Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00078247 |
Recruitment Status
:
Completed
First Posted
: February 23, 2004
Last Update Posted
: August 12, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Tuberculosis | Drug: Abacavir Drug: Lamivudine Drug: Zidovudine Drug: Tuberculosis treatment | Phase 3 |
Tuberculosis (TB) is a common and serious complication of HIV infection in the developing world, especially in sub-Saharan Africa. Since the emergence of the HIV epidemic in Africa, the incidence rates of TB have risen dramatically, overwhelming national TB control programs across the continent. Over 50% of TB patients presenting to TB clinics in Africa are HIV infected. These patients often present in the early stages of HIV infection.
Recent World Health Organization guidelines on the management of HIV-associated pulmonary TB recommend antiretroviral (ARV) therapy in patients with CD4 cells less than 200 cells/mm3, but not for HIV infected TB patients who present with a high CD4 count. In Uganda, over half of HIV infected patients with active TB present to TB clinics with CD4 counts above 200 cells/mm3, and there is evidence that coinfected patients with a high CD4 count should be treated with ARV therapy. First, mortality in HIV-associated TB is high, even when patients respond to effective anti-tuberculosis therapy. Second, excess mortality associated with TB is most evident when CD4 counts are above 200 cell/mm3. Third, in coinfected patients, TB results in prolonged immune activation, which may enhance viral replication and accelerate the decline of CD4 cells.
This study will evaluate whether short-term ARV therapy of abacavir sulfate, lamivudine, and zidovudine given during treatment of active TB will slow progression of HIV disease in TB patients with CD4 counts of at least 350 cells/mm3. The study will also assess the possible risks (e.g., drug toxicities and resistance) and benefits (e.g., more rapid clearance of mycobacterium tuberculosis and reduced TB relapse) of punctuated ARV therapy.
Participants in this study will be HIV infected TB patients with CD4 counts of at least 350 cells/mm3. All participants will receive treatment for TB. Participants will be randomly assigned to receive 6 months of ARV therapy or to delay ARV therapy until CD4 counts drop below 250 cells/mm3. The participants will be followed for 2 years; CD4 counts will be compared between groups.
This study will also follow a group of HIV infected patients without active TB to quantify the extent to which CD4 cell decline is accelerated with active TB and to determine the extent to which a decline is neutralized in patients who receive punctuated ARV therapy.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 350 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Delaying HIV Disease Progression With Punctuated Antiretroviral Therapy in HIV-Associated Tuberculosis |
Study Start Date : | October 2004 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
Participants will receive 6 months of ARV therapy and treatment for TB
|
Drug: Abacavir
300 mg tablet taken orally twice daily
Drug: Lamivudine
300 mg tablet taken orally daily
Drug: Zidovudine
300 mg tablet taken orally twice daily
Drug: Tuberculosis treatment
Tuberculosis treatment
|
Experimental: 2
Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
|
Drug: Abacavir
300 mg tablet taken orally twice daily
Drug: Lamivudine
300 mg tablet taken orally daily
Drug: Zidovudine
300 mg tablet taken orally twice daily
Drug: Tuberculosis treatment
Tuberculosis treatment
|
- CD4+ decline (slope) [ Time Frame: Throughout study ]
- Time to AIDS [ Time Frame: Throughout study ]
- Safety [ Time Frame: Throughout study ]
- Response to antituberculous therapy [ Time Frame: Throughout study ]
- Immune reconstitution [ Time Frame: Throughout study ]
- Viral drug resistance [ Time Frame: Throughout study ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 60 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of pulmonary TB (AFB smear-positive or culture-positive)
- HIV infected
- CD4 count greater than 350 cells/mm3
- Residence within 20 km of Kampala, Uganda
- Willing to use acceptable forms of contraception during the study and for 6 weeks after stopping study medication
- Parent or guardian willing to provide informed consent, if applicable
Exclusion Criteria:
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00078247
Uganda | |
Makerere University Medical School | |
Kampala, Uganda |
Principal Investigator: | Christopher C. Whalen, MD | Case Western Reserve University | |
Principal Investigator: | Roy Mugerwa, MD | Makerere University | |
Principal Investigator: | Diane Havlir, MD | University of California, San Francisco |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Christopher C. Whalen, MD, Case Western Reserve University |
ClinicalTrials.gov Identifier: | NCT00078247 History of Changes |
Other Study ID Numbers: |
1R01AI051219-01A2 ( U.S. NIH Grant/Contract ) |
First Posted: | February 23, 2004 Key Record Dates |
Last Update Posted: | August 12, 2010 |
Last Verified: | August 2010 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Antiretroviral Therapy Africa |
Additional relevant MeSH terms:
HIV Infections Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections |
Bacterial Infections Lamivudine Zidovudine Abacavir Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents Antimetabolites |